We are live on ! Find out more
AMAG

AMAG Pharmaceuticals
AMAG

Delisted

AMAG was delisted on the 13th of November, 2020.

Back to rankings

173 hedge funds and large institutions have $898M invested in AMAG Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 49

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

12% more capital invested

Capital invested by funds: $803M → $898M (+$95.6M)

2% more funds holding

Funds holding: 170 → 173 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

26% less call options, than puts

Call options by funds: $5.66M | Put options by funds: $7.63M

Holders
173
Holders Change
+3
Holders Change %
+1.76%
% of All Funds
3.96%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
20
Increased
68
Reduced
49
Closed
16
Calls
$5.66M
Puts
$7.63M
Net Calls
-$1.98M
Net Calls Change
+$7.32M

Top Buyers

Rank Fund Capital Flow
1
JSP
Jackson Square Partners
California
+$59.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.6M
3
Macquarie Group
Macquarie Group
Australia
+$11.1M
4
SEI Investments
SEI Investments
Pennsylvania
+$10.6M
5
OM
Opaleye Management
Massachusetts
+$9.29M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$12.1M
2
TAM
Tocqueville Asset Management
New York
-$4.88M
3
PAM
Panagora Asset Management
Massachusetts
-$3.62M
4
JGC
J. Goldman & Co
New York
-$3.05M
5
UBS Group
UBS Group
Switzerland
-$2.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$8.19M +$9.29M +420,000 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$7.96M -$285K -12,880 -3%
Charles Schwab
28
Charles Schwab
California
$7.95M +$771K +34,833 +9%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$7.88M +$772K +34,894 +9%
Invesco
30
Invesco
Georgia
$7.09M +$2.97M +134,054 +58%
Norges Bank
31
Norges Bank
Norway
$5.72M – – –
Principal Financial Group
32
Principal Financial Group
Iowa
$5.32M +$110K +4,992 +2%
Deutsche Bank
33
Deutsche Bank
Germany
$4.88M -$167K -7,536 -3%
Ameriprise
34
Ameriprise
Minnesota
$4.83M +$1.06M +47,945 +24%
CEI
35
Clark Estates Inc
New York
$4.78M – – –
TCIM
36
TIAA CREF Investment Management
New York
$4.65M +$270K +12,211 +5%
FP
37
Foundry Partners
Minnesota
$4.21M -$556K -25,125 -10%
PAM
38
Panagora Asset Management
Massachusetts
$3.87M -$3.62M -163,842 -45%
VCM
39
Voce Capital Management
California
$3.58M +$38.2K +1,726 +0.9%
Two Sigma Investments
40
Two Sigma Investments
New York
$3.27M +$1.34M +60,676 +57%
Prudential Financial
41
Prudential Financial
New Jersey
$3.13M +$1.07M +48,148 +43%
Goldman Sachs
42
Goldman Sachs
New York
$2.96M -$383K -17,300 -10%
SI
43
Sofinnova Investments
California
$2.78M +$3.15M +142,511 New
Wells Fargo
44
Wells Fargo
California
$2.71M -$461K -20,823 -13%
OAM
45
Oxford Asset Management
United Kingdom
$2.23M +$817K +36,923 +50%
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
$2.23M +$1.63M +73,560 +181%
Bank of America
47
Bank of America
North Carolina
$2.04M +$1.49M +67,552 +182%
PCM
48
Piermont Capital Management
Missouri
$2.04M +$90.7K +4,100 +4%
Morgan Stanley
49
Morgan Stanley
New York
$2.02M -$204K -9,233 -8%
QI
50
QS Investors
New York
$1.94M +$288 +13 +0%
1
2
3 4 5

AMAG Hedge Fund Activity: Q2 2018 in Review

173 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2018, worth a combined $898M — up 12% from $803M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AMAG positions and 16 closed out — a net gain of 4 holders — while 68 added to existing stakes and 49 trimmed.

The largest buyer was Jackson Square Partners, opening a new position worth an estimated $59.2M. The largest seller was Broadfin Capital, exiting entirely with an estimated $12.1M sold.

  • 173 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2018, up from 170 in Q1 2018.
  • Funds reported $898M of AMAG Pharmaceuticals stock for Q2 2018, up 12% quarter-over-quarter.
  • 20 funds opened new AMAG Pharmaceuticals positions in Q2 2018 and 16 closed out, a net change of +4 holders.
  • The largest AMAG Pharmaceuticals buyer in Q2 2018 was Jackson Square Partners, an estimated $59.2M added.
  • The largest AMAG Pharmaceuticals seller in Q2 2018 was Broadfin Capital, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2018.